IRVING, TX--(MARKET WIRE)--Nov 12, 2008 -- DelSite, Inc. (OTC BB:DSII.OB - News) today announced that the United States Patent and Trademark Office has granted a Notice of Issuance of patent application No. 10/422,867, titled "High Molecular Weight, Low Methoxyl Pectins and their Production and Uses," relating to the Company's proprietary GelSite® polymer technology. DelSite Biotechnologies, Inc., a subsidiary of DelSite, Inc., is developing and commercializing GelSite® polymer as a controlled-release drug delivery technology for therapeutics and vaccine products.
The issued patent covers the basic composition of the novel plant pectins or polygalacturonic acids (GelSite® polymer), based on its distinct properties that are not found with related natural or synthetic polymers. The claims of this patent are broadly applicable to any use of GelSite® polymer and extend to use in pharmaceutical compositions including proteins, peptides, vaccine antigens and other pharmacological substances.
DelSite has successfully developed the manufacturing process for GelSite® polymer. It is now manufactured under cGMP at a kilogram scale with a purity of > 99%. A Drug Master File for this polymer was filed with the FDA in 2005 and is being updated regularly, allowing streamlined regulatory review for any medical applications.
This is a huge milestone in new technology for treating third world country epidemics. No temperature controls and very long shelf lifes for vaccines will drastically reduce costs and provide ease of administration. In cases of biological warfare in the states, this product can be combined with medication and mailed to every household self-administraion.